AI assistant
ADHERIUM LIMITED — Director's Dealing 2025
Sep 4, 2025
64305_rns_2025-09-04_00e7c8a7-3d8d-4531-92d9-691ad919e374.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [594 x 96] intentionally omitted <==
Late Lodgement of Appendices 3Y
Melbourne, Australia – 5 September 2025 : Leading digital health company Adherium Limited (ASX: ADR) (the Company ) advises that two Appendices 3Y of Mr George Baran and Mr Lou Panaccio were lodged with the ASX today.
In respect of the late lodgement of the Appendices 3Ys, the Company confirms that the changes in notificable interests were not as a result of on-market trade. The Unlisted Options lapsed in accordance with their terms and the other issues were part of the Convertible Note Offer and ANREO Offer, with all the transactions being announced to the market.
The Company and Directors are aware of the requirements under ASX Listing Rule 3.19A and 3.19B.
The administrative oversight has not affected the Company’s current arrangement for ensuring timely notification in accordance with the Listing Rules, and the Company is confident that the arrangements it currently has in place are adequate and does not believe that any additional steps are required to ensure ongoing compliance with Listing Rule 3.19B. The Company considers the late lodgement of the Appendices 3Y to be an isolated incident.
- ENDS -
This ASX announcement was approved and authorised for release by the Board.
| Investor Enquiries | Media Enquiries: |
|---|---|
| Adherium Limited | Haley Chartres |
| [email protected] | H^CK Director |
| [email protected] |
About Adherium (ASX: ADR)
Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium’s own broad range of sensors connected to respiratory medications. Adherium’s Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com
Adherium Limited (ACN 605 352 510) Collins Square, Tower 4, Level 18, 727 Collins Street Melbourne VIC 3000 Australia www.adherium.com | www.hailie.com | [email protected]